

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
17 August 2023 (17.08.2023)



(10) International Publication Number  
**WO 2023/152349 A1**

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/5025 (2006.01)  
C07D 401/12 (2006.01) A61K 31/519 (2006.01)  
C07D 401/14 (2006.01) C07D 405/14 (2006.01)  
C07D 413/14 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2023/053416

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

13 February 2023 (13.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/267,956 14 February 2022 (14.02.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85  
Södertälje (SE).


(72) Inventors: **TERSTIEGE, Ina**; AstraZeneca AB, 151 85  
Södertälje (SE). **SCHIESSER, Stefan**; AstraZeneca AB,  
151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-  
TY**; Eastbrook House, Shaftesbury Road, Cambridge Cam-  
bridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IRAK4 INHIBITORS



(57) Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.

WO 2023/152349 A1